#United States #Parker Waichman #Port Washington #Ozempic #NAION

Parker Waichman LLP Takes Legal Action on Behalf of Injury Victims

On May 4, 2026, Parker Waichman LLP announced that it has initiated multiple lawsuits against Novo Nordisk, the manufacturer of the diabetes medications Ozempic and Wegovy. The lawsuits arise from alarming reports of patients developing Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a serious and irreversible eye condition potentially leading to permanent vision loss.

The firm’s legal actions have intensified following the recent case of a South Carolina resident who experienced NAION after being prescribed Ozempic. This has added to a growing list of complaints from individuals across the nation who have reported severe eye-related issues tied to these popular GLP-1 receptor agonists. Historically aimed at treating Type 2 diabetes, these medications have gained traction for their off-label use in weight management, raising urgent safety concerns among healthcare practitioners and patients alike.

The Connection Between Semaglutide and NAION

Recent studies have painted a troubling picture concerning the safety profile of the active ingredient in Ozempic and Wegovy, semaglutide. Within a study published in JAMA Ophthalmology in 2025, nine subjects reported various optic nerve disorders, with symptoms closely resembling those associated with NAION. More strikingly, research by Harvard’s Mass Eye and Ear Institute found that diabetic patients using semaglutide were four times more likely to suffer from NAION compared to those who did not. Furthermore, non-diabetic patients utilizing the drug specifically for weight loss faced a staggering sevenfold increased risk of developing serious vision issues.

Despite these alarming findings, Novo Nordisk has reportedly downplayed the potential risks associated with their drugs, leading critics and legal representatives to argue that the company is neglecting its responsibility to provide consumers and healthcare professionals with crucial warnings.

Expert Voice: A Call to Action

According to Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP, “NAION represents a life-altering diagnosis. Empirical research from credible institutions underpins the relationship between semaglutide and NAION. However, Novo Nordisk's failure to acknowledge these findings threatens patient safety and accountability in pharmaceutical practices.”
Goldstein urges individuals who might have been affected to seek legal assistance to understand their rights and explore potential claims for compensation.

Seeking Justice for Victims

Parker Waichman LLP is currently extending their services to individuals who have faced sudden vision loss or related complications after taking Ozempic or Wegovy. Victims may qualify for compensation covering medical expenses, lost income, pain and suffering, among other damages.

Victims or their families are encouraged to contact Parker Waichman LLP to discuss their cases in a free consultation—thereby ensuring their rights are preserved and enabling them to pursue the justice they deserve.

For more information, individuals can reach Parker Waichman at 1-800-YOUR-LAWYER (1-800-968-7529) or visit their official website at YourLawyer.com.

About Parker Waichman LLP

Parker Waichman LLP has established itself as a prominent law firm specializing in holding pharmaceutical companies accountable for their negligence. With a history of successfully litigating cases involving defective drugs and dangerous products, the firm aims to protect victims from corporate malfeasance and secure fair compensation. Their commitment to justice has resulted in billions recovered for their clients in various contexts.